Identifying and Treating Familial Hypercholesterolemia

Details & Video

Program Time: 30 minutes

Accreditation-CME Credits: This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.

Target Audience: General Practitioners

Program available until: September 25, 2019

Program Preview

Click image above to play the program preview.

Full Program

Click here to view the full program

Overview & Objectives

Identifying and Treating Familial Hypercholesterolemia

Target Audience: General Practitioners.

By participating in this educational program, health care providers will be able to:

Examine the prevalence and risk associated with FH
Review the strategies to recognize potential FH patients
Identify optimal treatment strategies for FH

Accreditation

This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.

This program was supported in part by educational funding from Amgen Canada.

Claiming your credits: Please submit your credits for this activity online at www.cfpc.ca/login. Please retain proof of your participant for six (6) years in case you are selected to participate in credit validation or auditing.

Planning Committee & Faculty

Milan Gupta

MD, FRCPC, FCCS

Associate Clinical Professor of Medicine,
McMaster University
Medical Director
Canadian Collaborative Research Network
View disclosures

Brampton, ON

Jeffrey Habert

M.D., CMFC, FCMF

Assistant Professor,
University of Toronto,
Dept. of Family and Community Medicine
View disclosures

Toronto, Ontario

Daniel Ngui

B. Sc., PT, M.D., FCMF

Clinical Associate Professor
University of British Columbia
Medical Director
Fraser Street Medical
View disclosures

Vancouver, BC

Marla Shapiro

C.M., M.D.C.M., CMFC, M. Sc. S., FRCPC, FCMF, NCMP

Professor, University of Toronto
Department of Family and Community Medicine
University Health Network
North York General, Mount Sinai
View disclosures

Toronto, Ontario

Faculty

Rob Hegele

MD, FRCPC, FACP, FAHA, FCAHS, FCCS

Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function
Martha G. Blackburn Chair in Cardiovascular Research
Director, London Regional Genomics Centre
Scientist, Molecular Medicine, Robarts Research Institute
Distinguished University Professor, Departments of Medicine (Division of Endocrinology) and Biochemistry, Western University
View disclosures

London, Ontario

Agenda

Program Chapter	Duration (Min:Sec)
Introduction	2:02
Patient case	5:34
Prevalence of FH	4:39
Associated CV risk	4:03
Identifying potential FH patient	2:29
Treatment strategies	4:31
Practical considerations and summary	2:08

Sponsorship

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:

Amgen Canada

Links & Resources

Links & Resources:

Yuan et al. CMAJ 2006; 174:1124-9
Adapted from Nordestgaard BG et al. Eur Heart J 2013;34:3478-90a
Adapted from Austin MA et al. Am J Epidemiol 2004;160:421-9; Genest J et al. Can J Cardiol 2014;30:1471-81
Ruel, I et al. in review
Genest J. et al. Can J Cardiol. 2014; 30:1471-81
Defesche JC et al. Nat. Rev. Dis. Primers 2017 doi:10.1038/nrdp.2017.93
Adapted from Kastelein, JJP et al. As presented during ESC Congress 2015, Abstract 5772.
Raal F et al. Lancet 2015;385:331-40